3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Interventions
Cyclophosphamide
13
Etoposide
10
Prednisone
8
Doxorubicin
8
Whole-Body Irradiation
7
Vincristine
7
Rituximab
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Brentuximab Vedotin
7
romidepsin
6
fludarabine phosphate
6
Mycophenolic Acid
6
fludarabine
5
Lenalidomide
5
Gemcitabine
5
Cytarabine
5
10-propargyl-10-deazaaminopterin
5
Tacrolimus
4
Granulocyte Colony-Stimulating Factor
4
Carmustine
4
Busulfan
4
Antilymphocyte Serum
4
pembrolizumab
3
etoposide phosphate
3
carmustine, poliferprosan 20 drug combination
3
Vorinostat
3
Sirolimus
3
Nivolumab
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts